Stifel reiterated a Buy rating on Revolution Medicines, saying he thought the RMC-6236 safety data were great and that the firm is encouraged by a case study detailing efficiency in a KRAS-G12V patient. The firm added that RMC-6291 data look great in KRAS-exposed patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
- Revolution’s RMC-6291 abstract ‘reads well on efficacy,’ says Stifel
- Revolution Medicines shares jump 13%, or $3.41, to $28.96
- JPMorgan biotech analysts hold an analyst/industry conference call
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast